S-1/A: Alpha Cognition Inc. Announces Offering of Common Shares and Pre-Funded Warrants

Alpha Cognition Inc. is offering 2,500,000 common shares and pre-funded warrants to purchase up to 2,500,000 additional common shares, aiming for a Nasdaq Capital Market listing.

Summary

• Alpha Cognition Inc. is offering 2,500,000 common shares at an assumed price of $10.00 per share.
• The company is also offering pre-funded warrants for purchasers whose ownership would exceed 4.99% (or 9.99%) of outstanding common shares.
• Each pre-funded warrant is exercisable for one common share at $0.0001 per share.
• The company has applied to list its common shares on the Nasdaq Capital Market under the symbol ACOG.
• The offering is contingent upon Nasdaq approval; if not approved, the offering will not proceed.
• The company's Board of Directors has approved a 1-for-25 reverse stock split, intended to meet Nasdaq's minimum share price requirement.
• The company intends to use the net proceeds from this offering to begin its efforts toward our commercialization and launch of ZUNVEYL in AD; further research and development of our pipeline product candidates; continued commercial CMC activities (chemistry, manufacturing, and controls); and for working capital and general corporate purposes, which may include funding capital expenditures, acquisitions, and investments.

Sentiment

Score: 6

Explanation: The document presents a mix of positive and negative aspects. FDA approval for ZUNVEYL is a significant achievement, but the company's financial situation and dependence on future capital raises temper the overall outlook.

Positives

• FDA approval for ZUNVEYL provides a foundation for commercialization.
• Planned Nasdaq listing could increase visibility and attract new investors.
• The company intends to use the net proceeds from this offering to begin its efforts toward its commercialization and launch of ZUNVEYL in AD; further research and development of its pipeline product candidates; continued commercial CMC activities (chemistry, manufacturing, and controls); and for working capital and general corporate purposes, which may include funding capital expenditures, acquisitions, and investments.

Negatives

• The offering is contingent on Nasdaq approval, creating uncertainty.
• The company has incurred significant losses since its inception.
• The company will need substantial additional capital to meet its financial obligations and to pursue its business objectives, including the commercialization of ZUNVEYL oral tablet formulation.

Risks

• The company's ability to generate revenue and achieve profitability depends significantly on its ability to achieve commercial success with ZUNVEYL oral tablet formulation, its one FDA approved product and continued development and commercialization of its other product candidates, if approved.
• The company may encounter substantial delays in its preclinical studies and clinical trials or may not be able to conduct or complete its preclinical studies or clinical trials on the timelines it expects, if at all.
• The market opportunities for ZUNVEYL oral tablet formulation may be smaller than the company anticipates.
• The company relies on third -party suppliers to manufacture its product candidates, and it intends to rely on third parties to produce commercial supplies of ZUNVEYL and any other approved product.
• The successful commercialization of the company's product candidates will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels and pricing policies.

Future Outlook

The company plans to begin commercialization of ZUNVEYL, pursue out-licensing of its intranasal formulation for TBI, and continue its commercialization preparations.

Industry Context

The company operates in the biopharmaceutical industry, focusing on neurodegenerative diseases like Alzheimer's, where there is a high unmet need for effective treatments.

Comparison to Industry Standards

• The document mentions Biogen's Aduhelm and Corium's Adlarity as recent Alzheimer's treatments, providing a context for Alpha Cognition's ZUNVEYL.
• The document references the acetylcholinesterase inhibitor class of drugs, including donepezil, rivastigmine, and galantamine, as current treatments for Alzheimer's, against which ZUNVEYL will compete.
• The document mentions Vasopharm, SanBio/Sumitomo, Ostuka/Avanir Pharmaceuticals, Biogen, and Cellvation as companies currently in clinical trials for TBI, providing a context for Alpha Seven's ALPHA -1062 Intranasal (ALPHA -1062IN ) program.

Management Changes

Related Party Transactions

• The company has a loan agreement with Alpha Seven Therapeutics, Inc., a related party through a common director and officers, to advance an amount up to $150,000.
• The company has outstanding warrants denominated in both Canadian and U.S. Dollars.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from the offering and reverse stock split.
• Patients with Alzheimer's disease may benefit from the commercialization of ZUNVEYL.
• Employees may be affected by the company's ability to secure funding and execute its business strategy.

Next Steps

• Begin commercialization of the FDA-approved ZUNVEYL oral formulation.
• Continue commercialization preparations around ZUNVEYL.
• Complete the out-license the TBI asset into Alpha Seven in Q1 2025, where Alpha Seven plans to raise the additional capital to advance the TBI program.

Key Dates

Keywords

common shares, pre-funded warrants, Nasdaq, ZUNVEYL, offering, capital raise, reverse stock split, Alpha Cognition